Search

Displaying results 4471 - 4480 of 10000 in total
  1. Drug

    Apazunersen

    go.drugbank.com/drugs/DB16981
    Investigational

    Apazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]

    Categories: Antisense Oligonucleotide Specific to the Antisense Transcript of UBE3A
  2. Drug

    Quinidine barbiturate

    go.drugbank.com/drugs/DB01346
    Approved

    A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909) … The administration of quinidine derivatives helps to observe various skin and mucosal reactions.

    Products: NATISEDINE 100 MG TABLET, 20 ADET
  3. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. … [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.

    Mixtures: FLATON ENTERIK DRAJE, 60 ADET, FLATON ENTERIK DRAJE, 30 ADET
  4. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation

  5. Drug

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10798
    ApprovedInvestigational

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … meningitidis* serogroup a.

    Synonyms: Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen, Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine
  6. Drug

    Acer saccharinum pollen

    go.drugbank.com/drugs/DB10735
    Approved

    Acer saccharinum pollen is the pollen of the Acer saccharinum plant. Acer saccharinum pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  7. Drug

    Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine

    go.drugbank.com/drugs/DB16757
    Approved

    [A245819] Plant-based VLPs offer a number of advantages as compared to other vaccine platforms, including speed and ease of manufacturing and increased immunogenicity. … [L40694] While the concept of plant-based VLPs as vaccines is not new,[A245824] it is a novel approach to COVID-19 vaccination, with previously approved COVID-19 vaccines mostly comprising viral vector

  8. Drug

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10799
    ApprovedInvestigational

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  9. Drug

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10800
    ApprovedInvestigational

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  10. Drug

    Pramiracetam

    go.drugbank.com/drugs/DB13247
    Approved

    Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].